

# Ilona Kryczek

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3894396/publications.pdf>

Version: 2024-02-01

55  
papers

19,384  
citations

61857

43  
h-index

155451

55  
g-index

55  
all docs

55  
docs citations

55  
times ranked

24096  
citing authors

#	ARTICLE	IF	CITATIONS
1	CD8+ T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4. <i>Cancer Cell</i> , 2022, 40, 365-378.e6.	7.7	250
2	DOT1L affects colorectal carcinogenesis via altering T cell subsets and oncogenic pathway. <i>OncImmunology</i> , 2022, 11, 2052640.	2.1	4
3	Metabolism drives macrophage heterogeneity in the tumor microenvironment. <i>Cell Reports</i> , 2022, 39, 110609.	2.9	46
4	Loss of Optineurin Drives Cancer Immune Evasion via Palmitoylation-Dependent IFNGR1 Lysosomal Sorting and Degradation. <i>Cancer Discovery</i> , 2021, 11, 1826-1843.	7.7	42
5	The ubiquitin ligase MDM2 sustains STAT5 stability to control T cell-mediated antitumor immunity. <i>Nature Immunology</i> , 2021, 22, 460-470.	7.0	50
6	IFN $\gamma$ Augments Clinical Efficacy of Regulatory T-cell Depletion with Denileukin Diftitox in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3661-3673.	3.2	6
7	Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance. <i>Cancer Cell</i> , 2021, 39, 480-493.e6.	7.7	71
8	LIMIT is an immunogenic lncRNA in cancer immunity and immunotherapy. <i>Nature Cell Biology</i> , 2021, 23, 526-537.	4.6	96
9	Autophagy inhibition by targeting PIKfyve potentiates response to immune checkpoint blockade in prostate cancer. <i>Nature Cancer</i> , 2021, 2, 978-993.	5.7	52
10	Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. <i>Nature Medicine</i> , 2021, 27, 152-164.	15.2	451
11	Cancer SLC43A2 alters T cell methionine metabolism and histone methylation. <i>Nature</i> , 2020, 585, 277-282.	13.7	280
12	Autophagic adaptation to oxidative stress alters peritoneal residential macrophage survival and ovarian cancer metastasis. <i>JCI Insight</i> , 2020, 5, .	2.3	59
13	Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy. <i>Journal of Clinical Investigation</i> , 2020, 130, 2712-2726.	3.9	112
14	Radiotherapy and Immunotherapy Promote Tumoral Lipid Oxidation and Ferroptosis via Synergistic Repression of SLC7A11. <i>Cancer Discovery</i> , 2019, 9, 1673-1685.	7.7	566
15	Inhibition of ATM Increases Interferon Signaling and Sensitizes Pancreatic Cancer to Immune Checkpoint Blockade Therapy. <i>Cancer Research</i> , 2019, 79, 3940-3951.	0.4	154
16	CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy. <i>Nature</i> , 2019, 569, 270-274.	18.7	1,528
17	miR-508 Defines the Stem-like/Mesenchymal Subtype in Colorectal Cancer. <i>Cancer Research</i> , 2018, 78, 1751-1765.	0.4	30
18	Spatial and phenotypic immune profiling of metastatic colon cancer. <i>JCI Insight</i> , 2018, 3, .	2.3	73

#	ARTICLE	IF	CITATIONS
19	Aerobic Glycolysis Controls Myeloid-Derived Suppressor Cells and Tumor Immunity via a Specific CEBPB Isoform in Triple-Negative Breast Cancer. <i>Cell Metabolism</i> , 2018, 28, 87-103.e6.	7.2	263
20	Human Naive T Cells Express Functional CXCL8 and Promote Tumorigenesis. <i>Journal of Immunology</i> , 2018, 201, 814-820.	0.4	18
21	Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. <i>Journal of Clinical Investigation</i> , 2018, 128, 805-815.	3.9	423
22	IL33 Promotes Colon Cancer Cell Stemness via JNK Activation and Macrophage Recruitment. <i>Cancer Research</i> , 2017, 77, 2735-2745.	0.4	144
23	Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor. <i>Nature Immunology</i> , 2017, 18, 1332-1341.	7.0	508
24	Phenotype and tissue distribution of CD28H+ immune cell subsets. <i>Oncolmmunology</i> , 2017, 6, e1362529.	2.1	13
25	<i>Fusobacterium nucleatum</i> Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy. <i>Cell</i> , 2017, 170, 548-563.e16.	13.5	1,377
26	Suppression of FIP200 and autophagy by tumor-derived lactate promotes naïve T cell apoptosis and affects tumor immunity. <i>Science Immunology</i> , 2017, 2, .	5.6	83
27	Myeloid-Derived Suppressor Cells Endow Stem-like Qualities to Breast Cancer Cells through IL6/STAT3 and NO/NOTCH Cross-talk Signaling. <i>Cancer Research</i> , 2016, 76, 3156-3165.	0.4	224
28	Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer. <i>Cell</i> , 2016, 165, 1092-1105.	13.5	340
29	Inflammatory regulatory T cells in the microenvironments of ulcerative colitis and colon carcinoma. <i>Oncolmmunology</i> , 2016, 5, e1105430.	2.1	27
30	PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer. <i>Cancer Research</i> , 2016, 76, 275-282.	0.4	204
31	Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction. <i>Nature Immunology</i> , 2016, 17, 95-103.	7.0	310
32	Th22 cells control colon tumorigenesis through STAT3 and Polycomb Repression complex 2 signaling. <i>Oncolmmunology</i> , 2016, 5, e1082704.	2.1	29
33	Myeloid cells in hepatocellular carcinoma. <i>Hepatology</i> , 2015, 62, 1304-1312.	3.6	123
34	Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. <i>Nature</i> , 2015, 527, 249-253.	13.7	897
35	IL-22+CD4+ T Cells Promote Colorectal Cancer Stemness via STAT3 Transcription Factor Activation and Induction of the Methyltransferase DOT1L. <i>Immunity</i> , 2014, 40, 772-784.	6.6	309
36	Tumor-Associated Macrophages Produce Interleukin 6 and Signal via STAT3 to Promote Expansion of Human Hepatocellular Carcinoma Stem Cells. <i>Gastroenterology</i> , 2014, 147, 1393-1404.	0.6	529

#	ARTICLE	IF	CITATIONS
37	Myeloid-Derived Suppressor Cells Enhance Stemness of Cancer Cells by Inducing MicroRNA101 and Suppressing the Corepressor CtBP2. <i>Immunity</i> , 2013, 39, 611-621.	6.6	366
38	Interleukin-10 Ablation Promotes Tumor Development, Growth, and Metastasis. <i>Cancer Research</i> , 2012, 72, 420-429.	0.4	129
39	Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. <i>International Journal of Cancer</i> , 2012, 130, 29-39.	2.3	230
40	Human T <sub>H</sub> 17 Cells Are Long-Lived Effector Memory Cells. <i>Science Translational Medicine</i> , 2011, 3, 104ra100.	5.8	236
41	IL-17+ Regulatory T Cells in the Microenvironments of Chronic Inflammation and Cancer. <i>Journal of Immunology</i> , 2011, 186, 4388-4395.	0.4	224
42	Response: Endogenous IL-17, tumor growth, and metastasis. <i>Blood</i> , 2010, 115, 2556-2557.	0.6	15
43	FOXP3 Defines Regulatory T Cells in Human Tumor and Autoimmune Disease. <i>Cancer Research</i> , 2009, 69, 3995-4000.	0.4	177
44	Endogenous IL-17 contributes to reduced tumor growth and metastasis. <i>Blood</i> , 2009, 114, 357-359.	0.6	354
45	Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. <i>Blood</i> , 2009, 114, 1141-1149.	0.6	688
46	Induction of IL-17+ T Cell Trafficking and Development by IFN- $\gamma$ : Mechanism and Pathological Relevance in Psoriasis. <i>Journal of Immunology</i> , 2008, 181, 4733-4741.	0.4	433
47	Cutting Edge: IFN- $\gamma$ Enables APC to Promote Memory Th17 and Abate Th1 Cell Development. <i>Journal of Immunology</i> , 2008, 181, 5842-5846.	0.4	83
48	Cutting Edge: Th17 and Regulatory T Cell Dynamics and the Regulation by IL-2 in the Tumor Microenvironment. <i>Journal of Immunology</i> , 2007, 178, 6730-6733.	0.4	375
49	Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis. <i>American Journal of Physiology - Cell Physiology</i> , 2007, 292, C987-C995.	2.1	290
50	Relationship between B7-H4, Regulatory T Cells, and Patient Outcome in Human Ovarian Carcinoma. <i>Cancer Research</i> , 2007, 67, 8900-8905.	0.4	294
51	Cutting Edge: Induction of B7-H4 on APCs through IL-10: Novel Suppressive Mode for Regulatory T Cells. <i>Journal of Immunology</i> , 2006, 177, 40-44.	0.4	252
52	B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. <i>Journal of Experimental Medicine</i> , 2006, 203, 871-881.	4.2	638
53	Regulatory T Cells in Ovarian Cancer: Biology and Therapeutic Potential. <i>American Journal of Reproductive Immunology</i> , 2005, 54, 369-377.	1.2	197
54	Dendritic Cell Subsets Differentially Regulate Angiogenesis in Human Ovarian Cancer. <i>Cancer Research</i> , 2004, 64, 5535-5538.	0.4	270

#	ARTICLE	IF	CITATIONS
55	Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Medicine, 2004, 10, 942-949.	15.2	4,442